WO2007084868A3 - Treatment of disorders by activation of the unfolded protein response - Google Patents

Treatment of disorders by activation of the unfolded protein response Download PDF

Info

Publication number
WO2007084868A3
WO2007084868A3 PCT/US2007/060527 US2007060527W WO2007084868A3 WO 2007084868 A3 WO2007084868 A3 WO 2007084868A3 US 2007060527 W US2007060527 W US 2007060527W WO 2007084868 A3 WO2007084868 A3 WO 2007084868A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
unfolded protein
protein response
disorders
activation
Prior art date
Application number
PCT/US2007/060527
Other languages
French (fr)
Other versions
WO2007084868A2 (en
Inventor
Christian Hassig
Timothy C Gahman
Mark R Herbert
Angelina M Thayer
Original Assignee
Kalypsys Inc
Christian Hassig
Timothy C Gahman
Mark R Herbert
Angelina M Thayer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc, Christian Hassig, Timothy C Gahman, Mark R Herbert, Angelina M Thayer filed Critical Kalypsys Inc
Publication of WO2007084868A2 publication Critical patent/WO2007084868A2/en
Publication of WO2007084868A3 publication Critical patent/WO2007084868A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a novel method for the treatment of diseases by activating the unfolded protein response (UPR), or of inhibiting the expression of the inducible isoform of the nitric oxide synthase (iNOS) enzyme, or both. New methylpyrazole compounds which activate the UPR, downregulate iNOS, and reduce inflammatory markers are disclose herein, as are compositions comprising said compounds and their applications as pharmaceuticals for the treatment of disease.
PCT/US2007/060527 2006-01-17 2007-01-12 Treatment of disorders by activation of the unfolded protein response WO2007084868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76104306P 2006-01-17 2006-01-17
US60/761,043 2006-01-17

Publications (2)

Publication Number Publication Date
WO2007084868A2 WO2007084868A2 (en) 2007-07-26
WO2007084868A3 true WO2007084868A3 (en) 2007-11-08

Family

ID=37873150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/060527 WO2007084868A2 (en) 2006-01-17 2007-01-12 Treatment of disorders by activation of the unfolded protein response

Country Status (1)

Country Link
WO (1) WO2007084868A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155689B1 (en) * 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
MA33085B1 (en) 2008-12-19 2012-03-01 Boehringer Ingelheim Int Premedine-4 annular carboxamide as antagonists of the receptor ccr2 for the treatment of infections, asthma and COPD
JP5632014B2 (en) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 receptor antagonists and uses thereof
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
US20140031389A1 (en) * 2011-04-13 2014-01-30 Inserm (Institut National De La Sante Et De La Recherche Mdeicale) Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CN104302640A (en) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-diaminopyrazole kinase inhibitors
WO2013192165A2 (en) * 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN104725366B (en) * 2015-02-28 2018-06-19 南通大学 The preparation method and purposes of the trifluoromethyl pyrazol oxime derivatives of the thiadiazoles structure of alkoxy containing 5-
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
JP6400247B1 (en) * 2015-11-16 2018-10-03 ロンザ・リミテッド Process for the preparation of 1-methyl-3- (trifluoromethyl) -1H-pyrazol-5-ol
CN105712932B (en) * 2016-03-08 2019-01-22 南通大学 A kind of preparation and application of the pyrazoles oxime ether compound of -3- of methyl containing 1- aryl -4- chlorine pyrrazole structure
JP6714785B2 (en) * 2018-05-31 2020-06-24 クミアイ化学工業株式会社 Process for producing fluorine-containing pyrazole derivative and intermediate thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052941A1 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US20050130989A1 (en) * 2003-01-28 2005-06-16 Aventis Pharma S. A. N-arylheteroaromatic products compositions containing them and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052941A1 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US20050130989A1 (en) * 2003-01-28 2005-06-16 Aventis Pharma S. A. N-arylheteroaromatic products compositions containing them and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARALDI P G ET AL: "DESIGN, SYNTHESIS, DNA BINDING, AND BIOLOGICAL EVALUATION OF WATER-SOLUBLE HYBRID MOLECULES CONTAINING TWO PYRAZOLE ANALOGUES OF THE ALKYLATING CYCLOPROPYLPYRROLOINDOLE (CPI) SUBUNIT OF THE ANTITUMOR AGENT CC-1065 AND POLYPYRROLE MINOR GROOVE BINDERS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 16, 2 August 2001 (2001-08-02), pages 2536 - 2543, XP008049613, ISSN: 0022-2623 *
DENNY, WILLIAM A. ET AL: "Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity", JOURNAL OF MEDICINAL CHEMISTRY , 28(11), 1568-74 CODEN: JMCMAR; ISSN: 0022-2623, 1985, XP002427761 *

Also Published As

Publication number Publication date
WO2007084868A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007084868A3 (en) Treatment of disorders by activation of the unfolded protein response
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008002570A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2008011363A3 (en) Quercetin-containing compositions
WO2008134646A3 (en) Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2008045664A3 (en) Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006031267A3 (en) Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2007107162A3 (en) Small internally segmented interfering rna
WO2006117217A3 (en) Novel use of spiegelmers
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2009099942A3 (en) Chemically modified oligonucleotides and uses thereof
NO20082124L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2008011364A3 (en) Quercetin-containing compositions
WO2009145456A3 (en) Heterocyclic derivatives
WO2010144378A3 (en) Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
MY144970A (en) Heterocyclic compounds
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2007127487A3 (en) Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07710122

Country of ref document: EP

Kind code of ref document: A2